<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="69265">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02204111</url>
  </required_header>
  <id_info>
    <org_study_id>YonLife-2014</org_study_id>
    <nct_id>NCT02204111</nct_id>
  </id_info>
  <brief_title>Patient Directed Intervention to Improve the Quality of Life for Patients With Soft Tissue Sarcoma</brief_title>
  <acronym>YonLife</acronym>
  <official_title>Patient Directed Intervention Towards a Multidimensional Recommendation Guideline to Improve the Quality of Life for Patients With Soft Tissue Sarcoma Under Palliative Treatment With Trabectedin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GWT-TUD GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PharmaMar</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GWT-TUD GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to compare quality of life (QoL) between patients
      suffering from soft tissue sarcoma, receiving a multidimensional intervention with those
      receiving standard treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Health related QoL, measured by total score of FACT-G</measure>
    <time_frame>change to baseline at 9 weeks</time_frame>
    <description>assessed by the patient using standard questionnaire (FACT-G) via tablet-PC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dimensions of QoL (scales of FACT-G)</measure>
    <time_frame>baseline, 3, 6, 9, 21, 35 and 61 weeks</time_frame>
    <description>assessed by the patient using standard questionnaire (FACT-G) via tablet-PC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depression (HADS)</measure>
    <time_frame>baseline, 9, 21, 35 and 61 weeks</time_frame>
    <description>assessed by the patient using standard questionnaire (HADS) via tablet-PC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with care (IN-PATSAT32)</measure>
    <time_frame>baseline, 9, 21, 35 and 61 weeks</time_frame>
    <description>assessed by the patient using standard questionnaire (IN-PATSAT32) via tablet-PC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anorexia and cachexia related impact on QoL (FAACT)</measure>
    <time_frame>baseline, 9, 21, 35 and 61 weeks</time_frame>
    <description>assessed by the patient using standard questionnaire (FAACT) via tablet-PC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of pain and pain related interference (BPI)</measure>
    <time_frame>baseline, 9, 21, 35 and 61 weeks</time_frame>
    <description>assessed by the patient using standard questionnaire (BPI) via tablet-PC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of cancer-related symptoms (MDASI)</measure>
    <time_frame>baseline, 3, 6, 9, 21, 35 and 61 weeks</time_frame>
    <description>assessed by the patient using standard questionnaire (MDASI) via tablet-PC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>baseline up to 61 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>baseline up to 61 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">77</enrollment>
  <condition>Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>Control Cluster</arm_group_label>
    <description>Care as usual</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Cluster</arm_group_label>
    <description>Care as usual and patient directed, multidimensional treatment proposals</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intervention</intervention_name>
    <description>Individualized treatment proposals (e.g. pain therapy, physiotherapy, psychological contact) from expert consensus, based on Patient Reported Outcomes</description>
    <arm_group_label>Treatment Cluster</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Soft Tissue Sarcoma under palliative treatment with Trabectedin
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of advanced or metastatic soft tissue sarcoma

          -  Treatment with trabectedin in an in-label prescription

          -  Age at least 18 years (inclusive) at the first visit

          -  Patients with a life expectancy of at least 6 months

          -  The informed consent form must be signed before any study specific tests or
             procedures are done

          -  Confirmation of the subject's health insurance coverage prior to the first visit

          -  Ability to understand and follow study-related instructions

        Exclusion Criteria:

          -  ECOG PS &gt;2

          -  Estimated life expectancy of less than 6 months

          -  Patients with STS not receiving trabectedin

          -  Contraindications according to the local SmPC of Yondelis®

          -  Subject is in custody by order of an authority or a court of law

          -  Exclusion periods from other studies or simultaneous participation in other clinical
             studies

          -  Previous assignment to treatment during this study

          -  Close affiliation with the investigator (e.g. a close relative) or persons working at
             the study site

          -  Subject is an employee of GWT-TUD GmbH or Pharma Mar S.A.

          -  Criteria which in the opinion of the investigator preclude participation for
             scientific reasons, for reasons of compliance, or for reasons of the subject's safety
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Schuler, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Carl Gustav Carus, Dresden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Markus Schuler, Dr. med.</last_name>
    <phone>+49 (0) 351 458 - 0</phone>
    <email>Markus.Schuler@uniklinikum-dresden.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leopold Hentschel</last_name>
    <phone>+49 (0) 351 458 - 0</phone>
    <email>Leopold.Hentschel@uniklinikum-dresden.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Carl Gustav Carus, MK I</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Schuler, Dr. med.</last_name>
      <phone>+49 (0) 351 458 - 0</phone>
      <email>Markus.Schuler@uniklinikum-dresden.de</email>
    </contact>
    <contact_backup>
      <last_name>Leopold Hentschel</last_name>
      <phone>+49 (0) 351 458 - 0</phone>
      <email>Leopold.Hentschel@uniklinikum-dresden.de</email>
    </contact_backup>
    <investigator>
      <last_name>Markus Schuler, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Annegret Kunitz, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Viktor Gruenwald, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Koeln</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jens Chemnitz, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bernd Kasper, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Torsten Keßler, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hans-Georg Kopp, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>July 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Palliative Treatment</keyword>
  <keyword>Trabectedin</keyword>
  <keyword>Patient Reported Outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
